Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6-(4-deoxy-4-((2e,4e)-tetradecadienoylglycyl)amino-l-glycero-b-l-mannoheptopyranosyl)amino-9h-purine
2. Krn 5500
3. Krn-5500
4. Krn5500
1. Spicamycin Analog
2. Nsc650426
3. 151276-95-8
4. Krn5500
5. (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-[(1s)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide
6. Nsc-650426
7. Schembl1650068
8. Chembl1988585
9. (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide
10. 4-deoxy-n-(7h-purin-6-yl)-4-(((2,4-tetradecadienoylamino)acetyl)amino)heptopyranosylamine
11. (2e,4e)-n-[2-[[2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-(7h-purin-6-ylamino)tetrahydropyran-3-yl]amino]-2-oxo-ethyl]tetradeca-2,4-dienamide
12. 6-[4-deoxy-4-(tetradeca-2(e), 4(e)-dienoylglycyl)amino-l-glycero-.beta.-l-manno-hepto-pyranosyl]amino-9h-purine
| Molecular Weight | 589.7 g/mol |
|---|---|
| Molecular Formula | C28H43N7O7 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 17 |
| Exact Mass | 589.32239674 g/mol |
| Monoisotopic Mass | 589.32239674 g/mol |
| Topological Polar Surface Area | 215 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 880 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 6 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
ABOUT THIS PAGE
39
PharmaCompass offers a list of Spicamycin Analog API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Spicamycin Analog manufacturer or Spicamycin Analog supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Spicamycin Analog manufacturer or Spicamycin Analog supplier.
PharmaCompass also assists you with knowing the Spicamycin Analog API Price utilized in the formulation of products. Spicamycin Analog API Price is not always fixed or binding as the Spicamycin Analog Price is obtained through a variety of data sources. The Spicamycin Analog Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Spicamycin Analog manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Spicamycin Analog, including repackagers and relabelers. The FDA regulates Spicamycin Analog manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Spicamycin Analog API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Spicamycin Analog supplier is an individual or a company that provides Spicamycin Analog active pharmaceutical ingredient (API) or Spicamycin Analog finished formulations upon request. The Spicamycin Analog suppliers may include Spicamycin Analog API manufacturers, exporters, distributors and traders.
click here to find a list of Spicamycin Analog suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Spicamycin Analog DMF (Drug Master File) is a document detailing the whole manufacturing process of Spicamycin Analog active pharmaceutical ingredient (API) in detail. Different forms of Spicamycin Analog DMFs exist exist since differing nations have different regulations, such as Spicamycin Analog USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Spicamycin Analog DMF submitted to regulatory agencies in the US is known as a USDMF. Spicamycin Analog USDMF includes data on Spicamycin Analog's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Spicamycin Analog USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Spicamycin Analog suppliers with USDMF on PharmaCompass.
Spicamycin Analog Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Spicamycin Analog GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Spicamycin Analog GMP manufacturer or Spicamycin Analog GMP API supplier for your needs.
A Spicamycin Analog CoA (Certificate of Analysis) is a formal document that attests to Spicamycin Analog's compliance with Spicamycin Analog specifications and serves as a tool for batch-level quality control.
Spicamycin Analog CoA mostly includes findings from lab analyses of a specific batch. For each Spicamycin Analog CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Spicamycin Analog may be tested according to a variety of international standards, such as European Pharmacopoeia (Spicamycin Analog EP), Spicamycin Analog JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Spicamycin Analog USP).
